Press Room


    Press Release - April 10, 2001

    Pheromone Sciences Corp Receives Approval for U.S. Pivotal Trial

    Pheromone Sciences Corp (CDNX: PHS), today announced that it has received approval for its multi- center efficacy clinical trial of the PSC Fertility Monitor(tm).

    The trial, to be carried out in 140 subjects, will take place at Duke University, Raleigh N.C., under the direction of Dr. Arthur Haney, Professor of Obstetrics and Gynecology and at Thomas Jefferson University Hospital in Philadelphia under the direction of Dr. Stephen Corson, Professor, Obstetrics and Gynecology and Section Head, Reproductive Endocrinology. Patient recruitment will commence later this month with the study scheduled to report in Q-4, 2001.

    "With ever increasing numbers of women seeking assistance in order to achieve conception, the medical profession is constantly looking for innovative tools to assist in the process ", commented Duke University's Dr. Arthur Haney, Professor of Obstetrics and Gynecology. "As a non-invasive device that provides users with the opportunity to carry out home testing without urine or blood samples, the PSC Fertility Monitor offers a new level of convenience".

    The U.S. study follows on the heels of the positive clinical results previously reported from a pilot study conducted at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto. The trial demonstrated that the PSC Fertility Monitor' predicted ovulation within +/- 1.38 days of the actual date of ovulation, while also providing women with up to four days' advance notice. This accuracy compares favourably to other ovulation or fertility testing technologies and methods currently in use, none of which have the capacity to provide users with the same specific advance notice.

    "We remain committed to our goal of filing submissions with the FDA for marketing approval on the PSC Fertility Monitor' prior to year end," said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "To this end we will diligently continue efforts towards the receipt of U.S. regulatory approval and commercialization in 2002".

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News